We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Institute of Translational Neurology, University Hospital Münster (UKM), Münster, Germany
Professor Luisa Klotz studied medicine at the University of Bonn (Germany), graduating in 2002. Since 2011, she has been the group leader and head of the clinical trial unit “Neurology and IITs” at the Department of Neurology, University Hospital Münster. She holds a Professorship for “Neurological Immune Therapy,” and her research focuses on immunomodulatory properties of nuclear receptors, pathologic immune responses in multiple sclerosis (MS), and novel therapeutic approaches.
As a clinician scientist, Professor Klotz is particularly interested in the close and continuous integration of basic research and clinical translation. She therefore uses a wide range of methods to answer scientific questions, from animal experiments and studies on human immune cells to conducting her own scientifically oriented clinical studies. Professor Klotz conducts research at the DFG-funded collaborative research center TR128 and 1009, which will be a part of the “Body and Brain Institute Münster” in the future. Professor Klotz is the recipient of several awards, including the Sobek Young Scientist Award for Multiple Sclerosis in 2012 and the renowned DGN Science Award in 2019.
Disclosures: Has received compensation for serving on Scientific Advisory Board for Alexion, Biogen, Bristol-Myers Squibb, Genzyme, Hexal, Horizon, Janssen, Merck Serono, Novartis, Roche, Sandoz, Sanofi, and Viatris. Has received speaker honoraria and travel support from Argenx, Bayer, Biogen, Bristol-Myers Squibb, Genzyme, Grifols, Merck Serono, Novartis, Roche, Santhera, and Teva. Receives research support from the German Research Foundation, the IZKF Münster, Biogen, Immunic AG, Novartis, and Merck Serono.
University of Lille, Lille, France
Professor Patrick Vermersch studied medicine at the University Hospital in Lille, France, where he graduated in neurology. He then studied cellular biology from 1990-1994 and received a PhD in biochemical abnormalities associated with Alzheimer’s and other neurodegenerative diseases. This work inspired Professor Vermersch to turn his research interests to MS. In the year 2000, Professor Vermersch and colleagues created the first MS network in northern France, focused on improving MS research and care.
Professor Vermersch currently works in the Lille Neuroscience and Cognition Research Institute at the University of Lille, which focuses on MS and other neuroinflammatory diseases. The department’s principal scientific interests are neuroimmunology and markers of disease evolution.
In 2019, Professor Vermersch became a board member of the European Charcot Foundation. After serving as the vice president of biology and health research at the University of Lille, Professor Vermersch now serves as the director of the graduate school.
His current areas of interest are prognostic markers of MS, the development of new therapeutic targets, and general neuroimmunology. Professor Vermersch participates in many therapeutic protocols on MS as a member of multiple steering committees and has published approximately 480 scientific papers as author or co-author.
Disclosures: Has received speaker honoraria and contributions to attend meetings from Biogen, Sanofi, Novartis, Teva, Merck, Roche, Imcyse, AB Science, and BMS-Celgene. Has received research support from Novartis, Sanofi, and Roche.
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Or use a
.Explore the latest in medical education and stay current in your field. Create a free account to track your learning.